Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001314034 | SCV001504548 | uncertain significance | Noonan syndrome | 2023-10-13 | criteria provided, single submitter | clinical testing | This sequence change replaces asparagine, which is neutral and polar, with serine, which is neutral and polar, at codon 178 of the RRAS protein (p.Asn178Ser). This variant is present in population databases (rs762794552, gnomAD 0.004%). This variant has not been reported in the literature in individuals affected with RRAS-related conditions. ClinVar contains an entry for this variant (Variation ID: 1015206). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be tolerated. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV004671334 | SCV005164254 | uncertain significance | not specified | 2024-06-23 | criteria provided, single submitter | clinical testing | The p.N178S variant (also known as c.533A>G), located in coding exon 5 of the RRAS gene, results from an A to G substitution at nucleotide position 533. The asparagine at codon 178 is replaced by serine, an amino acid with highly similar properties. This amino acid position is conserved. In addition, the in silico prediction for this alteration is inconclusive. Based on the available evidence, the clinical significance of this variant remains unclear. |